In vitro and In vivo Assessment of Liposomes and Chitosan Microparticles as Potential Carriers for Intravesical Delivery of Oxybutynin in the Treatment of Over Active Bladder

R. Felemban, G.D. Souza, H. Nguyen, C. Gridley
MCPHS University, US

Keywords: liposomes, chitosan microparticles, intravesical delivery of oxybutynin, over active bladder


The unique structural features of the urinary bladder effectively prevent the diffusion of toxic substances from the urine to the blood. Overactive bladder (OAB) may benefit from intravesical drug delivery (IDD), which involves direct instillation of drug into the bladder via a catheter, to achieve high local concentrations of the drug with minimal systemic effects. Nanocarriers have been founds to enhance local effect in the bladder as well as target diseased cells. This research focuses more on in-vitro and in-vivo assessment of liposomal nanocarriers and chitosan microcarriers as potential carrier for intravesical drug delivery. Liposomal nanocarriers and chitosan microcarriers were formed via thin film hydration method and spray drying, respectively. Chitosan particles showed improved in vitro tissue penetration compared to liposomes. Both formulations improved drug accumulation in bladder tissue in vitro compared to free drug. Chitosan particles mediated significantly higher levels of drug accumulation in the bladder compared to liposomes. Liposomes significantly improved the spasmolytic effect of oxybutynin in vivo compared to the free drug. Taken together the data suggest that incorporation of oxybutynin into pharmaceutical carriers can improve the accumulation of oxybutynin in bladder tissue and potentially improve therapeutic effect upon intravesical administration.